Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

POLITICO Pro Morning Health Care, presented by Lilly: Brexit wobble — WHO DG candidates compete

November 4, 2016, Politico Pro

Brian Kelly and Grant Castle are quoted in a Politico Pro “Morning Health Care” article regarding the High Court ruling that the UK government does not have the legal power to invoke Article 50 without Parliamentary approval. According to Kelly, “This presents an opportunity for individual companies and the industry to engage with members of Parliament to ensure that their views are heard before a vote takes place.” However, in the meantime, before the appeal in the Supreme Court, “for the pharmaceutical industry this just means continued uncertainty over the timing and terms of any withdrawal,” he adds.

Castle says that despite the appeal process, the March date for invoking Article 50 may still be a possibility. “This date wasn’t plucked from thin air: it was based on the likely timing of these court proceedings … which are all being fast-tracked. By March, we should know whether the government can proceed with the notification as it originally planned or whether it needs a mandate from parliament, which may delay things.”


Share this article: